Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
暂无分享,去创建一个
Peter Bohlen | Robert S. Kerbel | S. Baruchel | D. Hicklin | P. Bohlen | R. Kerbel | S. Man | J. Rak | G. Klement | Sylvain Baruchel | Giannoula Klement | Janusz Rak | Shan Man | Katherine A. Clark | Daniel J. Hicklin | K. Clark | P. Bőhlen | Katherine A. Clark
[1] M. Dewhirst,et al. Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth. , 1997, The Journal of clinical investigation.
[2] A. Ullrich,et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. , 1999, Cancer research.
[3] J. Pober,et al. Control of apoptosis during angiogenesis by survivin expression in endothelial cells. , 2000, The American journal of pathology.
[4] D. Pode,et al. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. , 1999, The Journal of clinical investigation.
[5] C. Dinney,et al. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[6] M. Cumming,et al. Antiangiogenic potential of camptothecin and topotecan , 1999, Cancer Chemotherapy and Pharmacology.
[7] R. Saura,et al. A mechanism of cisplatin action: antineoplastic effect through inhibition of neovascularization. , 1997, The Kobe journal of medical sciences.
[8] J. Mulliken,et al. Antiangiogenic Therapy of a Recurrent Giant Cell Tumor of the Mandible With Interferon Alfa-2a , 1999, Pediatrics.
[9] N. Goldstein,et al. In vitro neutralization of vascular endothelial growth factor activation of Flk-1 by a monoclonal antibody , 1994 .
[10] D. Ribatti,et al. Antiangiogenesis Is Produced by Nontoxic Doses of Vinblastine , 1999 .
[11] R. Kerbel,et al. Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. , 1999, Biochemical and biophysical research communications.
[12] Thomas Boehm,et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance , 1997, Nature.
[13] Napoleone Ferrara,et al. Clinical applications of angiogenic growth factors and their inhibitors , 1999, Nature Medicine.
[14] R K Jain,et al. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[15] R. Saura,et al. Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. , 1989, Arthritis and rheumatism.
[16] E. Lamont,et al. The oral fluoropyrimidines in cancer chemotherapy. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[17] J. Stone,et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity , 1995, Nature Medicine.
[18] A. Quyyumi,et al. Endothelial progenitor cells as putative targets for angiostatin. , 1999, Cancer research.
[19] M. Ehrlich. DNA alterations in cancer : genetic and epigenetic changes , 2000 .
[20] D. Stram,et al. Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group studies. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] A. Passaniti,et al. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. , 1992, Laboratory investigation; a journal of technical methods and pathology.
[22] R. Weichselbaum,et al. Combined effects of angiostatin and ionizing radiation in antitumour therapy , 1998, Nature.
[23] J C Reed,et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. , 1998, Cancer research.
[24] R. Steiner. Angiostatic activity of anticancer agents in the chick embryo chorioallantoic membrane (CHE-CAM) assay. , 1992, EXS.
[25] Vishva Dixit,et al. Vascular Endothelial Growth Factor Regulates Endothelial Cell Survival through the Phosphatidylinositol 3′-Kinase/Akt Signal Transduction Pathway , 1998, The Journal of Biological Chemistry.
[26] L. Thomsen,et al. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. , 1991, European journal of cancer.
[27] R. Weichselbaum,et al. Blockade of the Vascular Endothelial Growth Factor Stress Response Increases the Antitumor Effects of Ionizing Radiation , 1999 .
[28] D. Ribatti,et al. Purine analogue 6-methylmercaptopurine riboside inhibits early and late phases of the angiogenesis process. , 1999, Cancer research.
[29] J. Folkman,et al. Anti‐Angiogenesis: New Concept for Therapy of Solid Tumors , 1972, Annals of surgery.
[30] D. Hicklin,et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. , 1999, Cancer research.
[31] H. Cohen,et al. Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[32] D. Mooney,et al. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. , 1999, The American journal of pathology.
[33] R K Jain,et al. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[34] I. Tannock. Population kinetics of carcinoma cells, capillary endothelial cells, and fibroblasts in a transplanted mouse mammary tumor. , 1970, Cancer research.
[35] J. Hainsworth,et al. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] M. Haber,et al. Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma. , 1994, Cancer research.
[37] J. Hoffmann,et al. Antiangiogenic chemotherapeutic agents: characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[38] T. Nomura,et al. Evaluation of antitumor activity in a human breast tumor/nude mouse model with a special emphasis on treatment dose , 1989, Cancer.
[39] J. Folkman,et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. , 2000, Cancer research.
[40] W. Evans,et al. Oral cancer chemotherapy: the promise and the pitfalls. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[41] Robert Langer,et al. Angiogenesis, Key principles, Science, Technology, Medicine , 1992 .
[42] J. Isner,et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow‐derived endothelial progenitor cells , 1999, The EMBO journal.
[43] G. Viale,et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[44] J. Denekamp,et al. Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy , 1993 .
[45] Leonard,et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. , 1997, Cancer research.
[46] B. Teicher,et al. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. , 1992, Cancer research.
[47] R. Kerbel,et al. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti‐cancer therapeutic agents , 1991, BioEssays : news and reviews in molecular, cellular and developmental biology.
[48] A. MacKenzie,et al. The inhibitors of apoptosis (IAPs) and their emerging role in cancer , 1998, Oncogene.
[49] R. Kerbel. Tumor angiogenesis: past, present and the near future. , 2000, Carcinogenesis.
[50] N. Weidner,et al. Endothelial cell proliferation in prostatic carcinoma and prostatic hyperplasia: correlation with Gleason's score, microvessel density, and epithelial cell proliferation. , 1995, Laboratory investigation; a journal of technical methods and pathology.
[51] I. Tannock,et al. The proliferation of capillary endothelial cells. , 1972, Cancer research.